 Janux Therapeutics Inc. received a bullish reception on its Wall Street debut, as shares of the California-based biotechnology company developing cancer treatments opened at double the upsized initial public offering price before paring some gains. The company raised 193.8 million as it sold 11.4 million shares in the IPO, which priced at 17 a share. 